Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT02740634
Status
Recruiting
Apply to this trial

Conditions

  • Alzheimer Disease
  • Alzheimer Disease, Early Onset
  • Amnestic Disorder
  • Amnestic Mild Cognitive Disorder
  • Amnestic Symptoms
  • Atypical Alzheimer's Disease
  • Logopenic Progressive Aphasia (LPA)
  • Posterior Cortical Atrophy (PCA)

Eligibility Criteria

Sex
ALL
Age
21 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • F-18 AV 1451 — DRUG
    Tau binding agent
  • C-11 PiB — DRUG
    Amyloid binding agent

Study Details

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

Key Dates

First listed
Apr 15, 2016
Start date
May 31, 2016
Status verified
Jul 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Tau PET Scan, F-18 AV 1451
    All subjects will receive two Tau PET scans during this study.
  • Experimental: PiB PET Scan, C-11 PiB
    All subjects will receive two PiB PET scans during this study.

Primary Outcome Measure

Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Sarah Boland, CCRP
[email protected]
507-284-3863

Find similar trials in Rochester, MN

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Mayo Clinic· Rochester, MN

Related Studies